Articles Published in 2013

Gliknik, Pfizer enter autoimmune disease licensing agreement

Monday, September 30, 2013 02:44 PM

Gliknik, a privately-held biopharmaceutical company, has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, Gliknik's recombinant stradomer, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

More... »

Parexel launches China Trials Solution

Monday, September 30, 2013 02:40 PM

Global CRO Parexel International has launched Parexel Dĭng Huī, China Trials Solution. The offering combines advanced technology and international SOPs (Standard Operating Procedures) with local experience and resources to deliver cost-effective services that meet global quality standards. Parexel Dĭng Huī will support clients through locally delivered, streamlined services that support single-country registration trials and are tailored to meet Chinese NDA submission requirements.

More... »

Report: British pharmaceutical market to reach $31.7 billion by 2020

Monday, September 30, 2013 02:39 PM

A growing disease burden, universal coverage and good access to healthcare facilities are boosting the U.K. healthcare market, but increasing use of generics and government cost-cutting measures to reduce expenditure are restricting further growth, according to research and consulting firm GlobalData.

More... »

H. D. Smith acquisition Triplefin

Monday, September 30, 2013 02:37 PM

H. D. Smith, a pharmaceutical wholesaler and services provider based in Springfield, Ill., has acquired Triplefin, a reimbursement, patient assistance and pharmaceutical brand-support services company headquartered in Cincinnati, Ohio. H. D. Smith secured majority representation on Triplefin's board of directors in January and majority stock ownership interest in May. H.D. Smith has now acquired the remaining 49% of Triplefin shares, giving the company full ownership.

More... »

Transcept, SNBL partner for acute migraine treatment

Monday, September 30, 2013 02:35 PM

Transcept Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of proprietary products to address therapeutic needs in neuroscience, and Shin Nippon Biomedical Laboratories (SNBL) have entered into an exclusive worldwide licensing agreement for a novel, rapidly absorbed treatment for acute migraine incorporating dihydroergotamine (DHE) as the active drug. 

More... »

CureDuchenne Ventures launched to accelerate drug discovery and development

Friday, September 27, 2013 01:24 PM

National nonprofit CureDuchenne has launched CureDuchenne Ventures, a new initiative to identify and develop a robust pipeline of therapies to treat Duchenne, the most common and lethal form of muscular dystrophy. This drug discovery and development initiative is based on CureDuchenne's venture philanthropy model, in which the organization provides early stage funding to biotechnology, pharmaceutical companies and academic investigators to help develop breakthrough therapies to treat Duchenne.

More... »

JSS Medical Research completes acquisition of LatAm Clinical Trials

Friday, September 27, 2013 01:23 PM

CRO JSS Medical Research has acquired LatAm Clinical Trials, a multinational CRO in South and Central America.

More... »

Cancer Research Technology Pioneer fund, BACIT, Sareum ink agreement

Friday, September 27, 2013 11:18 AM

The Cancer Research Technology Pioneer Fund (CPF), Battle Against Cancer Investment Fund (BACIT) and drug discovery company Sareum, have entered into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.

More... »

CANbridge, Azaya enter agreement

Friday, September 27, 2013 11:10 AM

CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, has partnered with Azaya Therapeutics in San Antonio, Texas, to develop and commercialize Azaya’s investigational drug, ATI-1123, for treatment of non-small cell lung cancer (NSCLC), and potentially other solid tumor cancer indications, in China, Taiwan and South Korea.

More... »

Global Health Investment Fund launched for late-stage vaccines

Friday, September 27, 2013 10:59 AM

A new investment fund structured by JPMorgan Chase and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.

More... »